GBCC, formerly known as Interpark Bioconvergence Corporation, is one of the earliest organizations developing patient derived organoids (PDOs) in global scale. We have over 500 PDOs from lung, gastric and colorectal cancer patients and are also developing co-culture systems using autologous immune cells and cancer-associated fibroblasts with our PDOs. Based on our genomic and drug response data, we are discovering and validating novel drug resistant oncology targets through our CRISPR-based PDO platform. Beyond cancer, GBCC is conducting research on brain organoid from human iPSC for disease modeling and regenerative medicine. In addition, we are developing human derived probiotics not only as health functional foods but also therapeutic agents through functional evaluation using our colon PDOs. | Gradiant Bioconvergence (GBCC) is one of the earliest organizations developing patient derived cancer organoids (PDOs) in global scale. We have built Asia’s largest repository of PDOs with next-generation sequencing of over 600 models from lung, gastric and colorectal cancer patients. In addition, we are developing co-culture systems using autologous immune cells and cancer-associated fibroblasts with our PDOs. Based on our genomic and drug response data, we are discovering and validating novel drug resistant oncology targets through our AI-driven target discovery and CRISPR-based PDO platform. Beyond cancer, GBCC is establishing brain organoids from human iPSCs for disease modeling and regenerative medicine. | Gradiant Bioconvergence (GBCC) is one of the earliest organizations developing patient derived cancer organoids (PDOs) in global scale. We have built one of Asia’s largest repository of PDOs with next-generation sequencing of over 800 models from lung, gastric and colorectal cancer patients. In addition, we are developing co-culture systems using autologous immune cells and cancer-associated fibroblasts with our PDOs. Based on our genomic and drug response data, we are discovering and validating novel drug resistant oncology targets through our AI-driven target discovery and CRISPR-based PDO platform. Beyond cancer, GBCC is establishing brain organoids from human iPSCs for disease modeling and regenerative medicine. | xxx
Evaluate
Evaluate radically transforms your confidence in strategic portfolio decisions. We are the leading provider of commercial intelligence and predictive analytics for the global pharmaceutical industry. We work with the world’s largest pharmaceutical corporations, financial services firms, management consultancies and service providers, as well as a wide range of innovative biotech and medtech companies. From an overview of the broader market to a detailed product or company analysis, Evaluate’s integrated platform is designed to take you from exploration to full understanding as quickly and accurately as possible. We help you: – Identify competitor developments and likely time to market – Forecast patient populations and product sales for a potential lead asset – Undertake NPV assessments based on modelling discounted cash flows – Manage clinical trial costing Evaluate offers a pharmaceutical Consulting & Analytics service designed to help clients address unique scientific, clinical and commercial challenges. Our pharmaceutical consulting services provide insight into: – Market Analysis & Competitor Intelligence – Corporate Strategy & Franchise Planning – Market Expansion & Forecasting – Mergers & Acquisition – New Product Development – Market Access and Pricing – Commercialization Evaluate is now a Norstella company: an organization that helps to ease and accelerate patient access to life-changing therapies. | Evaluate radically transforms your confidence in strategic portfolio decisions. In biopharma, making the right decisions has an incredible impact on patients’ lives. Making those decisions requires a deep understanding of your market; from identifying opportunities and mitigating risk to evaluating assets and pipelines. Evaluate provides a complete and dynamic view of the pharmaceutical market, with innovative solutions that bring together technology, real world data, and deep expertise to help you make portfolio decisions that drive growth. | Evaluate provides trusted commercial intelligence and forecasting models for the pharmaceutical industry. We help our clients to refine and transform their understanding of the past, present and future of the global biopharma market to drive better decisions. Evaluate’s solutions give you the time and confidence to turn understanding into insight, and insight into action. Market Sizing & Forecasting: Evaluate’s suite of forecasting solutions enables you to make confident investment, partnering, and commercial decisions. Gold-standard consensus forecasts provide an unmatched view into your markets, while custom forecast models, and proprietary analogs enable you to develop informed forecasts on your key assets. The result? A comprehensive view of the market – and your place in it. Business Development & Licensing: Every deal is different and requires a clear view of potential partners, comparable deals, and market potential. To support you, we go beyond asset assessment. Our solutions provide a systematic approach to enable you to compare candidates based on commercial, clinical, and scientific criteria such as market novelty, potential revenue, competitive intensity, and partner suitability. Portfolio Optimization & Asset Strategy: In an ever-evolving market landscape, you must understand the intricacies of clinical and commercial differentiation. Our comprehensive suite of solutions and insights give you the competitive edge you need to navigate the market’s complexities, optimize your pipeline, develop comprehensive scenario planning, and prioritize the right indications. Competitive Intelligence: For biotech and pharma companies alike, a comprehensive view of the competitive landscape is vital. Evaluate’s blend of data-driven solutions and expert analysis provide real-time tracking, analysis, and strategic intelligence to support decision-making processes across drug development, manufacturing, and market competition. So nothing need take you by surprise. Consulting & Analytics: Evaluate’s custom analytics team help you to address unique commercial challenges. We answer key asset, portfolio, and corporate strategy-related questions, powered by the combined resources of Norstella. With access to extensive data assets and experience across therapy areas and modalities, we partner with you to provide the answers you need to drive success.
Divamics Inc
Divamics Inc. is a cross-disciplinary company with the core technology of AI and physics force field, helping collaborators to hunt new hits and PCCs in a more efficient and accurate way, especially for undrugable targets. Also, we offer clinical insights, such as resistance analyses and expansion of drug indications. Our signature capacities include drug design for GPCR, allosteric sites, and PPI, transcription factors. Our targeting modalities cover small molecules, peptides, PROTAC, XDC, synthetic biology, and more. We have already collaborated with 25+ MNCs/bioteches to advance over 35 new drug development pipelines and achieved multiple breakthrough results. Our records include: *FIC Project: Pioneering Drug Development* 1. Proposed binding site hypotheses, enabling the creation of drugs from scratch 2. Identified hits within 30 syntheses in a FIC pipeline with no pre-existing clinical drugs *BIC Project: Revolutionizing Structural Optimization* 1. Combined SAR computational analysis with expert medicinal chemistry insights to innovate structural optimization 2. Achieved patent breakthrough and better potency within just 6 syntheses of peptides, currently in Phase II clinical trials; Phase II clinical trial data to be presented at the ADA Conference, June 2024 We want to find collaborators such as the early discovery departments of MNCs, biopharmaceuticals and biotechs, with flexible cooperation modes including strategic joint research and others. | Divamics Inc. is a cross-disciplinary company with the core technology of AI and physics force field, helping collaborators to HUNT NEW LEADs and PCCs in a more efficient and accurate way, especially for UNDRUGGABLE targets. Also, we offer clinical insights, such as resistance analyses and expansion of drug indications. Currently, we have 40+ partners (10 listed companies/MNCs, 2 USA biotechs) for 60 pipeline projects, while 2 of them have reached end of Phase Ⅲ. We work on strategic collaboration mode, or offer AI+DBDD services, based on our partners’ needs. | Divamics: Redefining the Speed of Precision Medicine Divamics is an AI-driven biotech leader accelerating the journey from hit identification to preclinical candidate (Hits-to-PCC). By integrating advanced AI with molecular dynamics, we provide biopharma partners with the clarity and confidence to make critical discovery decisions faster. With a proven track record of supporting 80+ pipelines for over 50 global partners, we have successfully reduced PCC discovery timelines to just 0.5 – 1.5 years. Our platform delivers unmatched precision across four key modalities: small molecules, peptides, antibodies, and nucleic acids.
CheckImmune GmbH
CheckImmune is an innovative immune biomarker CRO for preclinical and clinical programs. As a spin-off company of Charité Universitätsmedizin Berlin we have strong links to academic state-of-the art research. CheckImmune is providing biomarker studies with focus on novel immunotherapeutics (small molecules, biologics, Advanced Therapy Medicinal Products – ATMPs) and immunological challenges in other medical areas. CheckImmune is specialized in the development and validation of immunological biomarkers for global clinical trials and accredited according to ISO 17025 and 15189 with fulfilling the requirements of GCLP (Good Clinical Laboratory Practice). Our core expertise includes assay development and validation for Receptor Occupancy, Flow Cytometry, Multiplex Cytokine Analyses, Functional Tests, Single Cell Multiomics, and Tissue Biopsies. We are a certified service provider for 10x Genomics, Olink, and ProteinSimple Ella. We are a team of well recognized experts for immune biomarker analyses and data interpretation. Our Services are Selection/validation of drug lead candidates, Phase 0 studies with access to fresh patient material, Therapy monitoring (safety, efficacy/stratification) and Data analysis and scientific & medical interpretation. At CheckImmune, we develop highly specialized immunological biomarker assays and provide end-to-end lab services for clinical and preclinical trials. From assay design to regulatory-grade data analysis – we help biopharma companies understand immune responses with precision. We are a certified service provider for 10x Genomics, OLINK and bio-techne. With a track record of more than 90 industry-sponsored trials and 120,000 samples we have earned an excellent international reputation. Selection/validation of drug lead candidates Application of a broad panel of customized and off-the-shelf biomarker tests using cutting-edge technologies for lead candidate selection. Phase 0 studies with access to fresh patient material Proof-of-concept studies on biosamples from target patient populations (phase 0) to develop and confirm selected biomarker test portfolios for following therapy monitoring. Therapy monitoring Therapy monitoring in clinical trials to check safety, PD/PK, patient stratification with a wide range of validated assays as well as newly developed customized methods. Data analysis and scientific & medical interpretation CheckImmune is backed by a world-renowned team of experts with years of academic and commercial experience in the field of immune biomarkers. Technology used Our Technology platforms are – Complex Flow & Spectral Cytometry – Molecular & Multi-Omics Analysis: Bulk RNAseq, TCR /BCR repertoire, Single cell Multiomics (RNAseq, TCRseq, CITEseq) Spatial multi-omics, qRT- PCR (e.g. IFN signature) and digitalPCR – Multiplex Ligand Assays (MSD, Ella, OLINK) – Functional Assays – Anti-Drug Response (ADA/ADT)
Certara
Certara accelerates medicines using proprietary biosimulation software, technology and services to transform traditional drug discovery and development. Its clients include nearly 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across 66 countries. | Certara accelerates medicines using proprietary biosimulation software, technology and services to transform traditional drug discovery and development. Its clients include more than 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across 70 countries.
Celestia Diagnostics
Celestia Diagnostics develops lab tests and clinical bioinformatics systems to aid in the diagnosis and treatment of chronic complex conditions such as Long COVID, ME/CFS, and POTS.
Agricultural Technology Research Institute
To strengthen the commercialization and industrialization of agricultural research results, the Council of Agriculture (COA) completed the preparatory works and established Agricultural Technology Research Institute (ATRI) on January 1, 2014. Under the ATRI there are Animal Technology Research Center, Plant Technology Research Center, Aquatic Technology Research Center, Business Promotion Center, and Agricultural Policy Research Center respectively in charge of related affairs. ATRI was formed by combining the following agencies: DPIAB – Development Program of Industrialization for Agricultural Biotechnology AgriTI – Office for Agricultural Technology Industry ATIT – Animal Technology Institute Taiwan COAT – Commercialization Office of Agricultural Technology Mission and Task To create a framework for the industrialization of agricultural technology and the development of entrepreneurship, provision of agricultural technology and commercialization/industrialization service to agribusiness, agricultural groups and farmers. 1.To work collaboratively with academia, other research institutes, and private sectors to develop innovative and useful technologies for commercial production. 2.To commercialize and industrialize agriculture research results. To provide assistances to private sectors in strengthening competitiveness and promoting international markets. 3.To serve as an intermediary platform for policy think-tanks. 4.To combine all efforts in promoting the common interests in agricultural area. Facilitations of decision-making process to provide solid foundation for agricultural policies in all forms. | x | To strengthen the commercialization and industrialization of agricultural research outcomes, the Ministry of Agriculture (MOA) completed the preparatory work and established the Agricultural Technology Research Institute (ATRI) on January 1, 2014. Under the ATRI there are Planning and Development Department, Administrative Services Department, Animal & Plant Health and Production Research Center, Agricultural Facilities and Environment Research Center, Agricultural Input and Product Valorization Research Center, Agricultural Policy Research Center and Industrial Development Center respectively in charge of related affairs. ATRI was formed by combining the following agencies: DPIAB – Development Program of Industrialization for Agricultural Biotechnology AgriTI – Office for Agricultural Technology Industry ATIT – Animal Technology Institute Taiwan COAT – Commercialization Office of Agricultural Technology
Adlib Software
Adlib is the accuracy authority in AI-driven document automation for high-stakes, regulated industries. As the critical layer in front of IDP systems, LLMs, and RAG pipelines, Adlib ingests messy, multi-format content and transforms it into AI-ready, machine-navigable pipelines. The platform normalizes file types, applies fidelity-preserving rendering and advanced OCR, classifies and chunks content with citation anchors, enriches it with metadata, extracts information into structured data contracts, and validates outputs against each organization’s business and compliance rules. This results in compliant, searchable outputs and high-quality structured data that downstream systems can trust. Across Life Sciences, Energy, Insurance, Financial Services, and other regulated sectors, enterprises rely on Adlib to reduce human-in-the-loop reviews, increase retrieval precision and model accuracy, accelerate decision-making, and lower processing costs. For more than two decades, organizations such as Pfizer, Swiss Re, IAG, and JP Morgan have trusted Adlib to turn unstructured content into reliable, audit-ready data that safeguards compliance, drives performance, and ensures every decision is precise and AI-ready.